Topic: The Australian response to COVID-19 and where we stand now
Topic: Tertiary Diabetes Centres pivots for COVID-19
Topic: How the Credentialled Diabetes Educator was impacted
Topic: Primary Care response and effect of telehealth
Topic: ADA 2020 Key Abstracts and Posters in Continuous Glucose Monitoring
Topic: Avatars delivering healthcare– are we ready to learn from a bot?
Topic: Patient Education Resource Library (PERL) – filling the gap in remote education
Topic: Diabetes and COVID-19…data keeps us apart
Topic: COVID-19 – The results are in and the long term diabetes service impacts are…
Topic: Making the most of technology in Telehealth – a practical guide with case study
Topic: Increasing Time in Range in adult populations
Topic: Increasing Time in Range in paediatric populations
Topic: Technology in Diabetes: The Future is Here
Topic: Increasing Time in Range in adult populations
Topic: Increasing Time in Range in paediatric populations
Will is an economist, Senior Associate in the health program at Grattan Institute and lives with type 1 diabetes.
He joined Grattan in 2017, working for the higher education, household finances and health programs. Will runs workshops on data analysis, communication and visualisation, and is the author of a number of R packages for public policy in Australia.
Will has written extensively on COVID-19 and Australia’s public policy response since February.
The Australian Government’s response to the COVID-19 in March was eventually the right one: lockdown and suppress the virus.
This was successful through to June. But the outbreaks in Victoria and New South Wales pose new challenges for containing the spread of COVID-19 while managing the health and economic wellbeing of Australians under lockdown.
Tony is Director of the Department of Diabetes and Endocrinology at the Princess Alexandra Hospital, a pre-Eminent staff specialist for Queensland Health and an Adjunct Associate Professor with the Centres for Health Services Research at The University of Queensland.
Tony’s research interests are around models of care for management of diabetes. He has established an integrated model of care for the management of complex Type 2 diabetes, established a telehealth service delivering Endocrine services to a number of centres in rural and remote Queensland and tested the use of mHealth technology in a new model of care in a tertiary diabetes service.
Tony has over 100 peer reviewed publications and attracted over $9 million dollars in research funding. Tony has been on the Endocrinology expert group for “Therapeutic Guidelines” and on the expert advisory group for the NHMRC guidelines on Type 1 diabetes. He has been a previous sub-editor in Endocrinology for the Internal Medicine Journal.
Tony currently sits on council of the Australian Diabetes Society.
With COVID19 we have had to review our models of care to manage our vulnerable population of people with diabetes. These models of care are trying to minimise transmission of the virus by reducing patient and health professional contact and considering options for working from home. We’ll review a tertiary hospital diabetes outpatient’s response to COVID19 and the adoption of technologies to enable these changes in delivery of care. Barriers will be identified to the implementation of these technologies and future solutions to implementing these changes as “business as covid usual”
Susan Davidson, B Ec, B HSc, has held management positions in the corporate, public and not-for-profit sectors, most recently in health and diabetes.
Susan was appointed CEO of the Australian Diabetes Educators Association (ADEA) in May 2019. She previously held the position of General Manager NDSS with Diabetes Australia from 2009 to 2018, managing a budget of $42 million and overseeing delivery of products, services, education and assistance nationally to more than 1.3 million people with diabetes as well as delivery of education and information to health professionals.
In her spare time, Susan is heavily involved in community-building and events, holding leadership positions in several organisations.
As the COVID-19 pandemic developed, ADEA successfully advocated for access to telehealth for services delivered by Credentialled Diabetes Educators (CDEs). Prior to COVID-19, few CDEs utilised telehealth for service delivery. The pandemic necessitated rapid change and adoption of telehealth for delivery of diabetes education to ensure continuity of care for people with diabetes. ADEA played a significant role in assisting CDEs in successfully navigating through this period of change.
This session will: reflect on the learnings from the rapid pivot to telehealth service delivery, explore how telehealth has changed service delivery over the past 12 months, and the impact on CDEs and people with diabetes.
Dr Konrad Kangru gained his MBBS from University of Queensland in 2000. He has been in private Rural General Practice in the Whitsundays region of Queensland since 2005, where he has been a GP Supervisor and Medical Educator since 2009.
He has remained a very active advocate for improving the support of rural doctors, especially through the Rural Doctors Association of Queensland, having convened their 2011 and 2015 conferences.Dr Kangru has also undertaken and presented his research on the Self-Care of rural doctors, and has special interests in Medical Education and Diabetes management, particularly in up-skilling colleagues about this important condition.
Pascale has joined Abbott Diabetes Care as HCP Liaison Manager in 2018. Her role focuses on delivering medical information about Flash glucose monitoring technology and managing partnerships with diabetes specialists and diabetes organisations such as the ADEA and NADC.
Her background is in Biomedical Science and her PhD was awarded in 2011, from the University of Sydney, for her research on optimising bone integrity and architecture in paediatrics. She has also practised as a Dietitian in Australia and the UK, including metro and remote area before joining the industry in medical affairs. She has a strong interest in patient-centricity and how the use of technology in clinical management will contribute to better health and a sustainable healthcare services delivery.
This session will include multiple short video presentations of the latest clinical evidence in people with T1 and T2 diabetes, supporting HbA1c change as a marker of glycaemic control, ketoacidosis, all-cause and emergency hospitalisations, followed by treatment satisfaction and quality of life as primary outcomes.
Presented studies are evaluating the effect of Flash Glucose Monitoring and Continuous Glucose Monitoring systems and include a mix of randomised controlled trials and large population observational studies
Dr Tina Campbell is a health promotion specialist with extensive experience developing patient education resources, tools and programs. She is the Founder and Managing Director of Healthily, a Melbourne-based health technology company, specialising in patient education and behaviour change.
With a career in the health industry spanning two decades, Tina has led the development of Australia’s largest video library of patient and carer experiences, and designed and developed the GoShare Healthcare content distribution platform, a web application used by health professionals around Australia to deliver tailored education resources to their patients by email or SMS.
Tina completed her PhD at the Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne. Her randomised controlled trial evaluated the impact of a ‘patient narrative’ intervention program on self-efficacy and self-care behaviours in people with Type 2 Diabetes.
After receiving feedback from the NADC members during COVID-19 and hearing of the frustrations in their provision of remote education, the NADC, developed the Patient Education Resource Library (PERL) in partnership with Healthily (GoShare) & Western Sydney Diabetes.
PERL offers healthcare professionals access to an extensive library of patient education resources including fact sheets, videos, apps and websites.
This platform provides access to credible, evidence-based resources that can be sent to people with diabetes via SMS and/or email. This presentation will include a short demonstration of PERL for healthcare providers.
Associate Professor Clair Sullivan, who leads the Queensland Digital Academy Research Group at CHSR.
Clair graduated with Honours in Medicine from UQ and a Research Doctorate in Medicine from the University of Leeds. She is a fellow of the Royal Australasian College of Physicians, the Australian College of Health Informatics and the Australasian Institute of Digital Health. Recently, she was appointed Associate Professor of Medicine in Clinical Informatics at The University of Queensland and is Adjunct Professor, Faculty of Health, Queensland University of Technology.
She is widely published in clinical informatics and serves on several national advisory boards for digital health.
Covid 19 has created huge challenges for the healthcare system.
People living with diabetes are particularly at risk. One of the few things that can travel faster than COVID-19 is electrons! So digital health has been critical to our response. This talk outlines strategies and techniques for combating pandemics…digitallly
Professor Sophia Zoungas is the Head of Monash University’s School of Public Health and Preventive Medicine, and also leads the School’s Metabolism, Ageing and Genomics Division. She is an Endocrinologist with clinical appointments at both Alfred Health and Monash Health.
Sophia is the project lead for The Australian National Diabetes Audit (ANDA), a longstanding centralised quality assurance activity aiming to improve the quality of care provided to people attending primary, secondary and tertiary health care services (diabetes centres) for management of diabetes. ANDA is facilitated by the National Association of Diabetes Centres (NADC) and funded by the Australian Government Department of Health.
Sophia leads multiple clinical and health services research groups and collaborates extensively both locally and internationally, using her skills in clinical medicine, clinical trials and translation of evidence into practice in the specialty areas of diabetes, cardiovascular health, kidney disease and healthy ageing. She has over 200 publications in peer-reviewed journals including New England Journal of Medicine, Lancet, Annals of Internal Medicine, British Medical Journal, and Nature Reviews.
COVID-19 – reporting on the experiences of diabetes services.
Professor David O’Neal is the director and founder of the Diabetes Technology Diabetes Group based at the University of Melbourne, Department of Medicine at St Vincent’s Hospital, Melbourne. He has led
multiple studies in novel diabetes technology and closed loop insulin delivery with significant national and international collaborations involving clinicians, academics and industry.
He is a professor with The University of Melbourne and a senior consultant endocrinologist with the Department of Endocrinology at St Vincent’s Public Hospital. Professor O’Neal has appointments with the University of Melbourne, the University of Notre Dame and the University of Sydney where he is involved in undergraduate and postgraduate teaching.
He is the recipient of awards including the Diabetes Victoria Outstanding contribution to Diabetes award 2019, the JDRF-Australia Diabetes Research Innovation Award for an established researcher and has had publications cited as amongst the most influential in their field
The definition and concept of glucose time-in-range (TIR) will be discussed and related to HbA1c, the historical benchmark by which glycaemic control has been assessed. While the TIR measure is applicable to all people living with diabetes, and one recognises that there are many modulating factors, this presentation focuses on the potential of technology to increase TIR in adults with type 1 diabetes.
A brief overview of the technological options for glucose measurement, insulin dosing and delivery will be given. While there is evidence that recent technological advancements hold great promise for improving TIR in people living with diabetes, the reality can sometimes fall short of the potential shown in trial outcomes. Underlying reasons, which include the user experience, health-care professional resourcing and limitations of the technology itself will be examined.
Finally, emerging technological advancements which may enhance TIR in clinical practice without undue burden on the person living with diabetes will be described.
Dr Lori Laffel is Chief of the Pediatric, Adolescent and Young Adult Section and a Senior Investigator/Head of the Section on Clinical, Behavioral and Outcomes Research at the Joslin Diabetes Center, as well as a Professor of Pediatrics at Harvard Medical School. She has published more than 200 articles in peer reviewed journals. She also has been a member of the advisory board of the International Society of Pediatric and Adolescent Diabetes (ISPAD), a member of the Clinical Advisory Committee for the JDRF, and a member of JDRF’s Research Advisory Committee.
Dr. Laffel is actively involved with the American Diabetes Association (ADA), as a member of the Boston Leadership Board, a past member of the National Board of Directors of the ADA, the National Committee for Professional Practice Guidelines, chair on the ADA’s Working Group on Transitions in Care for Young Adults with Diabetes, and past chair of ADA’s Youth Strategies Committee. She is also a member of ADA’s Pathway Mentor Advisory Program. Dr. Laffel is a global editor for the journal Diabetic Medicine, the primary journal for Diabetes UK. Her research focuses on understanding and overcoming challenges to self-management in persons with diabetes in order to improve glycemic control as well as other biomedical and psychosocial outcomes. Her research also aims to optimize the use of diabetes technologies, including continuous glucose monitors and automated insulin delivery systems. She is the recipient of many NIH and foundation funded grants. She received ADA’s 2015 Outstanding Physician-Clinician Award, the Greater Boston Chamber of Commerce 2016 Pinnacle Award, and the 2016 University of Miami School of Medicine Hall of Fame Award.
Increasing Time in Range for Pediatric Populations – Lori Laffel MD MPH, Joslin Diabetes Center, Harvard Medical School Glycemic control remains suboptimal for the majority of young persons with type 1 diabetes in the United States and in many developed countries.
There is a global need to optimize glycemic control with improvements in both HbA1c and glucose time in range. Glucose time in range can be assessed with review of two weeks of CGM data. Pediatric patients should aim for a glucose time in range of >70%, which equals about 17 hours each day. Achievement of this glucose time in range is roughly equivalent to an HbA1c <7% or 53 mmol/mol.
Use of real-time CGM provides opportunities to increase glucose time in range. With improved performance of CGM devices, there has been increased uptake of CGM use, in the USA and in other countries. Recent studies suggest that use of real-time CGM may be more effective than intermittent scanning CGM in efforts to increase glucose time in range. There are a number of strategies to increase glucose time in range. First, increased frequency of insulin bolus dosing can increase time in range. Next, attending to dietary factors beyond carbohydrates, including both protein and fat content of meals, may help increase glucose time in range. Next, exercise, with greater energy expenditure, can likely lead to more glucose time in range. Finally, use of advanced closed loop insulin delivery systems can increase glucose time in range for young persons with type 1 diabetes.
Professor Partha Kar is National Specialty Advisor, Diabetes with NHS England and co-lead of Diabetes GIRFT with NHS Improvement.
He has led and delivered so far on (April 2016- till date):
• Type 1 Diabetes structured education platform for all ages
• Setting up a National Diabetes Advice line during COVID19
• Data around COVID19 and mortality related to diabetes
• Part of national team developing guidelines during COVID19
• Freestyle Libre being available on NHS -across country
• NHS Right Care Diabetes pathway
• Diabetes “Language Matters” document
• Type 1 diabetes NHS England web-resource – on NHS choices
• Introduction of Frailty into QoF treatment targets for diabetes care in NHS
• Availability of CGM to all T1D pregnant patients
• Diabetes Technology pathway development with multiple stakeholders
• Setting up pilot projects for diabulimia treatment in London & Wessex
• Introduction of Low Carbohydrate App into NHS Apps Library
• Developing DEVICES – a VR based programme on diabetes education
Other work has involved input in updating of driving guidelines in relation to use of technology in those living with diabetes, helping to develop a virtual reality programme to improve hospital safety and starting work on increased mental health access for diabetes patients across the NHS
Dr Partha Kar has been a Consultant in Diabetes & Endocrinology at Portsmouth Hospitals NHS Trust since 2008. He has been the Clinical Director of Diabetes from 2009-2015, being part of a multiple national award-winning department (HSJ Awards / BMJ Awards) due to its services and care provided.
He is the pioneer of the Super Six Diabetes Model which aims to deliver diabetes care differently and is recognised as one of the good examples of integrated care.
An avid user of social media such as twitter (@parthaskar) to engage with patients – and been recognised as a “Social media Pioneer” by HSJ in 2014.
He also writes a monthly blog for the BMJ, has a personal blog (“Sugar and Spice: Wish all things were nice”) and a podcast (“Sweet Talking”) He has also been:
*Co-creator of TAD (Talking About Diabetes) – TED talks from those with T1Diabetes
*Co- creator of Type 1 Diabetes comic (Volume 1 and 2)
*Setting up Type 1 Diabetes: Rise of the Machines – event on Closed Loops/DIY tech
*Creator of “Diabetes 101” an online support group of healthcare professionals during COVID19
This session will look at the role of technology in diabetes care, its evolution as well as how patient involvement has made industry rethink their strategy. This will look at the need for modernising diabetes care- and where governments and payors also need to look at to improve diabetes care